Laboratory of Clinical Pharmacology and Pharmacometrics, Graduate School of Pharmaceutical Sciences, Chiba University, Chiba, Japan.
The University of Tokyo Hospital, Tokyo, Japan.
CPT Pharmacometrics Syst Pharmacol. 2023 Aug;12(8):1132-1142. doi: 10.1002/psp4.12980. Epub 2023 Jun 12.
In this study, the ethnic ratios (ERs) of oral clearance between Japanese and Western populations were subjected to model-based meta-analysis (MBMA) for 81 drugs evaluated in 673 clinical studies. The drugs were classified into eight groups according to the clearance mechanism, and the ER for each group was inferred together with interindividual variability (IIV), interstudy variability (ISV), and inter-drug variability within a group (IDV) using the Markov chain Monte Carlo (MCMC) method. The ER, IIV, ISV, and IDV were dependent on the clearance mechanism, and, except for particular groups such as drugs metabolized by polymorphic enzymes or their clearance mechanism is not confirmative, the ethnic difference was found to be generally small. The IIV was well-matched across ethnicities, and the ISV was approximately half of the IIV as the coefficient of variation. To adequately assess ethnic differences in oral clearance without false detections, phase I studies should be designed with full consideration of the mechanism of clearance. This study suggests that the methodology of classifying drugs based on the mechanism that causes ethnic differences and performing MBMA with statistical techniques such as MCMC analysis is helpful for a rational understanding of ethnic differences and for strategic drug development.
在这项研究中,对 673 项临床研究中评估的 81 种药物的日本人和西方人群之间的口腔清除率的种族比(ER)进行了基于模型的荟萃分析(MBMA)。根据清除机制将药物分为八组,并使用马尔可夫链蒙特卡罗(MCMC)方法推断每组的 ER 以及个体间变异性(IIV)、研究间变异性(ISV)和组内药物间变异性(IDV)。ER、IIV、ISV 和 IDV 取决于清除机制,除了某些特定的组,例如由多态酶代谢的药物或其清除机制不确定的药物外,种族差异通常较小。种族间的 IIV 差异相当小,ISV 约为 IIV 的一半,即变异系数。为了在没有假阳性检测的情况下充分评估口腔清除率的种族差异,应在充分考虑清除机制的情况下设计 I 期研究。这项研究表明,基于导致种族差异的机制对药物进行分类并使用 MCMC 等统计技术进行 MBMA 的方法有助于合理理解种族差异并进行战略药物开发。